Skip to main content

Advertisement

SpringerLink
Log in

Expression of PAR-4 and PHLDA1 is prognostic for overall and disease-free survival in oral squamous cell carcinomas

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

PAR-4 is a tumor suppressor protein with a pro-apoptotic function and down-regulation of PAR-4 is seen in a variety of tumors. PHLDA1 gene overexpression has been shown to reduce cell proliferation and induce cell death in a variety of cell types. In this study, 229 cases of oral squamous cell carcinoma (OSCC), arranged in a tissue microarray, were analyzed by immunohistochemistry. PAR-4 expression was predominantly moderate to strong and expression of PHLDA1 was predominantly negative or weak. Cytoplasmic expression of PAR-4 was associated with advanced clinical stage. Expression of PHLDA1 was associated with advanced clinical stage of the tumour. Five-year overall and disease-free survival rates differed significantly between cases that did and cases that did not express PHLDA1, and by multivariate analysis, expression of PHLDA1 and PAR-4 were independent prognostic factors in OSCC patients. Expression of PAR-4 and PHLDA1 is altered in OSCC and might be a valuable prognostic indicator for this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Massano J, Regateiro FS, Januário G, Ferreira A (2006) Oral Squamous cell carcinoma: review of prognostic and predictive factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:67–76

    Article  PubMed  Google Scholar 

  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 (2012) CA Cancer J Clin 62(1):10–29

  3. da Saúde M (2011) Ministério da Saúde. Instituto Nacional do Câncer. Estimativa/2012. Incidência de Câncer no Brasil. Rio de. Janeiro, INCA

  4. Schoelch ML, Le QT, Silverman S Jr, McMillan A, Dekker NP, Fu KK, Ziober BL, Regezi JA (1999) Apoptosis-associated proteins and the development of oral squamous cell carcinoma. Oral Oncol 35(1):77–85

    Article  PubMed  CAS  Google Scholar 

  5. Coutinho-Camillo CM, Lourenço SV, Nishimoto IN, Kowalski LP, Soares FA (2010) Expression of Bcl-2 family proteins and association with clinicopathological characteristics of oral squamous cell carcinoma. Histopathology 57(2):304–316

    Article  PubMed  Google Scholar 

  6. Coutinho-Camillo CM, Lourenço SV, Nishimoto IN, Kowalski LP, Soares FA (2011) Caspase expression in oral squamous cell carcinoma. Head Neck 33(8):1191–1198

    Article  PubMed  Google Scholar 

  7. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674

    Article  PubMed  CAS  Google Scholar 

  8. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70

    Article  PubMed  CAS  Google Scholar 

  9. Zhao Y, Rangnekar VM (2008) Apoptosis and tumor resistance conferred by Par-4. Cancer Biol Ther 7:1867–1874

    Article  PubMed  CAS  Google Scholar 

  10. Cook J, Krishnan S, Ananth S, Sells SF, Shi Y, Walther MM, Linehan WM, Sukhatme VP, Weinstein MH, Rangnekar VM (1999) Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene 18:1205–1208

    Article  PubMed  CAS  Google Scholar 

  11. Kogel D, Reimertz C, Mech P, Poppe M, Fruhwald MC, Engemann H, Scheidtmann KH, Prehn JH (2001) Dlk/ZIP kinase-induced apoptosis in human medulloblastoma cells: requirement of the mitochondrial apoptosis pathway. Br J Cancer 85:1801–1808

    Article  PubMed  CAS  Google Scholar 

  12. Boehrer S, Chow KU, Puccetti E, Ruthardt M, Godzisard S, Krapohl A, Schneider B, Hoelzer D, Mitrou PS, Rangnekar VM, Weidmann E lymphocytes and inverse expressional patterns of par-4 and bcl-2 in acute lymphocytic leukemia. Hematol J 2:103–107

  13. Nagai MA, Gerhard R, Salaorni S, Fregnani JH, Nonogaki S, Netto MM, Soares FA (2010) Down-regulation of the candidate tumor suppressor gene PAR-4 is associated with poor prognosis in breast cancer. Int J Oncol 37(1):41–49

    Article  PubMed  CAS  Google Scholar 

  14. Moreno-Bueno G, Fernandez-Marcos PJ, Collado M, Tendero MJ, Rodriguez-Pinilla SM, Garcia-Cao I, Hardisson D, Diaz-Meco MT, Moscat J, Serrano M, Palacios J (2007) Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res 67:1927–1934

    Article  PubMed  CAS  Google Scholar 

  15. Lee JW, Hsiao WT, Lee KF, Sheu LF, Hsu HY, Hsu SB, Lee MS, Hsu YC, Chang CH (2010) Widespread expression of prostate apoptosis response-4 in nasopharyngeal carcinoma. Head Neck 32(7):877–885

    PubMed  Google Scholar 

  16. Frank D, Mendelsohn CL, Ciccone E, Svensson K, Ohlsson R, Tycko B (1999) A novel pleckstrin homology-related gene family defined by Ipl/Tssc3, TDAG51, and Tih1: tissue-specific expression, chromosomal location, and parental imprinting. Mamm Genome 10(12):1150–1159

    Article  PubMed  CAS  Google Scholar 

  17. Park CG, Lee SY, Kandala G, Lee SY, Choi Y (1996) A novel gene product that couples TCR signaling to Fas(CD95) expression in activation-induced cell death. Immunity 4(6):583–591

    Article  PubMed  CAS  Google Scholar 

  18. Gomes I, Xiong W, Miki T, Rosner MR (1999) A proline- and glutamine-rich protein promotes apoptosis in neuronal cells. J Neurochem 73(2):612–622

    Article  PubMed  CAS  Google Scholar 

  19. Hossain GS, van Thienen JV, Werstuck GH, Zhou J, Sood SK, Dickhout JG, de Koning AB, Tang D, Wu D, Falk E, Poddar R, Jacobsen DW, Zhang K, Kaufman RJ, Austin RC (2003) TDAG51 is induced by homocysteine, promotes detachment-mediated programmed cell death, and contributes to the development of atherosclerosis in hyperhomocysteinemia. J Biol Chem 278(32):30317–30327

    Article  PubMed  CAS  Google Scholar 

  20. Neef R, Kuske MA, Pröls E, Johnson JP (2002) Identification of the human PHLDA1/TDAG51 gene: down-regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation. Cancer Res 62:5920–5929

    PubMed  CAS  Google Scholar 

  21. Nagai MA, Fregnani JHTG, Netto MM, Brentani MM, Soares FA (2007) Down-regulation of PHLDA1 gene expression is associated with breast cancer progression. Breast Cancer Res Treat 106:49–56

    Article  PubMed  CAS  Google Scholar 

  22. Shrestha-Bhattarai T, Rangnekar VM (2010) Cancer-selective apoptotic effects of extracellular and intracellular Par-4. Oncogene 29(27):3873–3880

    Article  PubMed  CAS  Google Scholar 

  23. Goswami A, Ranganathan P, Rangnekar VM (2006) The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target. Cancer Res 66(6):2889–2892

    Article  PubMed  CAS  Google Scholar 

  24. Qiu G, Ahmed M, Sells SF, Mohiuddin M, Weinstein MH, Rangnekar VM (1999) Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4. Oncogene 18(3):623–631

    Article  PubMed  CAS  Google Scholar 

  25. Burikhanov R, Zhao Y, Goswami A, Qiu S, Schwarze SR, Rangnekar VM (2009) The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 138(2):377–388

    Article  PubMed  CAS  Google Scholar 

  26. Sharma AK, Kline CL, Berg A, Amin S, Irby RB (2011) The Akt Inhibitor Isc-4 Activates Prostate Apoptosis Response Protein-4 and Reduces Colon Tumor Growth in a Nude Mouse Model. Clin Cancer Res 17(13):4474–4483

    Article  PubMed  CAS  Google Scholar 

  27. Chaudhry P, Singh M, Parent S, Asselin E (2012) Prostate Apoptosis Response-4 (Par-4): A Novel Substrate of Caspase-3 during Apoptosis Activation. Mol Cell Biol 32(4):826–839

    Article  PubMed  CAS  Google Scholar 

  28. Oberst MD, Beberman SJ, Zhao L, Yin JJ, Ward Y, Kelly K (2008) TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation. BMC Cancer 8:189

    Article  PubMed  Google Scholar 

  29. Toyoshima Y, Karas M, Yakar S, Dupont J, Lee H, LeRoith D (2004) TDAG51 mediates the effects of insulin-like growth factor I (IGF-I) on cell survival. J Biol Chem 279:25898–25904

    Article  PubMed  CAS  Google Scholar 

  30. Oberg HH, Sipos B, Kalthoff H, Janssen O, Kabelitz D (2004) Regulation of T-cell death-associated gene 51 (TDAG51) expression in human T-cells. Cell Death Differ 11(6):674–684

    PubMed  CAS  Google Scholar 

  31. Johnson EO, Chang KH, de Pablo Y, Ghosh S, Mehta R, Badve S, Shah K (2011) PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer. J Cell Sci 124(Pt 16):2711–2722

    Article  PubMed  CAS  Google Scholar 

  32. Sakthianandeswaren A, Christie M, D’Andreti C, Tsui C, Jorissen RN, Li S, Fleming NI, Gibbs P, Lipton L, Malaterre J, Ramsay RG, Phesse TJ, Ernst M, Jeffery RE, Poulsom R, Leedham SJ, Segditsas S, Tomlinson IP, Bernhard OK, Simpson RJ, Walker F, Faux MC, Church N, Catimel B, Flanagan DJ, Vincan E, Sieber OM (2011) PHLDA1 Expression Marks the Putative Epithelial Stem Cells and Contributes to Intestinal Tumorigenesis. Cancer Res 71(10):3709–3719

    Article  PubMed  CAS  Google Scholar 

  33. Ohyama M, Terunuma A, Tock CL, Radonovich MF, Pise-Masison CA, Hopping SB, Brady JN, Udey MC, Vogel JC (2006) Characterization and isolation of stem cell-enriched human hair follicle bulge cells. J Clin Invest 116:249–260

    Article  PubMed  CAS  Google Scholar 

  34. Sellheyer K (2011) Stem cell markers can help identify adnexal tumor differentiation when evaluated in the context of morphology: methodology matters. J Cutan Pathol 38(6):460–474

    Article  PubMed  Google Scholar 

  35. Sellheyer K, Nelson P (2011) Follicular stem cell marker PHLDA1 (TDAG51) is superior to cytokeratin-20 in differentiating between trichoepithelioma and basal cell carcinoma in small biopsy specimens. J Cutan Pathol 38:542–550

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

FAPESP (Fundação de Amparo à Pesquisa do Estado de São Paulo) research grants 98/14335-2, 07/50608-4, and 08/57887-9.

Author information

Authors and Affiliations

  1. Department of Anatomic Pathology, AC Camargo Cancer Center, São Paulo, Brazil

    Cláudia Malheiros Coutinho-Camillo, Suely Nonogaki & Fernando Augusto Soares

  2. Department of General Pathology, Dental School, University of São Paulo, São Paulo, Brazil

    Silvia Vanessa Lourenço & Fernando Augusto Soares

  3. Department of Otorhinolaryngology and Head and Neck Surgery, Hospital AC Camargo, São Paulo, Brazil

    José Guilherme Vartanian & Luiz Paulo Kowalski

  4. Discipline of Oncology, Department of Radiology and Oncology, Medical School, University of São Paulo, São Paulo, Brazil

    Maria Aparecida Nagai

  5. AC Camargo Cancer Center, Centro Internacional de Pesquisa, Rua Taguá, 440, São Paulo, 01508-010, Brazil

    Cláudia Malheiros Coutinho-Camillo

Authors
  1. Cláudia Malheiros Coutinho-Camillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Silvia Vanessa Lourenço
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Suely Nonogaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. José Guilherme Vartanian
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria Aparecida Nagai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Luiz Paulo Kowalski
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Fernando Augusto Soares
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cláudia Malheiros Coutinho-Camillo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Coutinho-Camillo, C.M., Lourenço, S.V., Nonogaki, S. et al. Expression of PAR-4 and PHLDA1 is prognostic for overall and disease-free survival in oral squamous cell carcinomas. Virchows Arch 463, 31–39 (2013). https://doi.org/10.1007/s00428-013-1438-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-013-1438-9

Keywords

Search

Navigation